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A study on the AMACR catalysed elimination
reaction and its application to inhibitor testing†
Maksims Yevglevskis,a Guat L. Lee,a Jenny Sun,a,b Shiyi Zhou,a,b Xiaolong Sun,c
Gabriele Kociok-Köhn,c Tony D. James,c Timothy J. Woodmana and
Matthew D. Lloyd*a
α-Methylacyl-CoA racemase (AMACR; P504S) catalyses a key step in the degradation of branched-chain
fatty acids and is important for the pharmacological activation of Ibuprofen and related drugs. Levels of
AMACR are increased in prostate and other cancers, and it is a drug target. Development of AMACR as a
drug target is hampered by lack of a convenient assay. AMACR irreversibly catalyses the elimination of HF
from 3-ﬂuoro-2-methylacyl-CoA substrates, and this reaction was investigated for use as an assay.
Several known inhibitors and alternative substrates reduced conversion of 3-ﬂuoro-2-methyldecanoyl-
CoA by AMACR, as determined by 1H NMR. The greatest reduction of activity was observed with known
potent inhibitors. A series of novel acyl-CoA esters with aromatic side chains were synthesised for testing
as chromophoric substrates. These acyl-CoA esters were converted to unsaturated products by AMACR,
but their use was limited by non-enzymatic elimination. Fluoride sensors were also investigated as a
method of quantifying released ﬂuoride and thus AMACR activity. These sensors generally suﬀered from
high background signal and lacked reproducibility under the assay conditions. In summary, the elimination
reaction can be used to characterise inhibitors, but it was not possible to develop a convenient colori-
metric or ﬂuorescent assay using 3-ﬂuoro-2-methylacyl-CoA substrates.
Introduction
α-Methylacyl-CoA racemase (AMACR, P504S; E.C. 5.1.99.4) cata-
lyses a key step in the degradation of branched-chain fatty
acids.1–3 The enzyme catalyses the conversion of either epimer
of a 2-methylacyl-CoA ester into a ca. 1 : 1 mixture of 2R- and
2S-epimers.4,5 β-Oxidation of 2-methylacyl-CoAs requires 2S-
configuration,6,7 but both R- and S-2-methylacyl-CoAs are pro-
duced in vivo and are derived from dietary fatty acids.3 Thus,
AMACR enables metabolism of R-2-methylacyl-CoAs. It is also
important in the pharmacological activation of R-Ibuprofen
and related drugs.3,5,8 AMACR has also been proposed to be
involved in the uni-directional chiral inversion of mandelic
acid in mammals9 but this was recently disproved.10
AMACR protein levels and enzyme activity are increased in
prostate cancers,11,12 myxofibrosarcomas,13 a subset of colon
cancers14 and various other cancers8 and it is widely recog-
nised as a promising drug target.3,8,15–18 Genetic knock-
down of AMACR reduces proliferation of cultured cancer
cells13,15,16,19 and restores androgen-dependent growth in
some prostate cancer cell lines.16 Relatively few chemical
inhibitors of AMACR have been reported,17–20 largely due to
the lack of a convenient, high-throughput assay. Current assay
methods include wash-out of tritium from a labelled substrate
followed by measurement of radioactive water1,2,19 or wash-in
of deuterium from D2O followed by
1H NMR analyses.4,5,10
These assays are probably subject to a kinetic isotope eﬀect,
and are low-throughput and labour-intensive. In addition, the
1H NMR assay also suﬀers from signal overlap of the substrate/
product 2-methyl group, thus making it more diﬃcult to quan-
tify activity. Characterisation of AMACR inhibitors using HPLC
assays17,18 has also been reported, but these assays are also
low throughput. Despite these diﬃculties, one of the identified
inhibitor pro-drugs, trifluoroibuprofen, shows promising anti-
prostate cancer eﬀects in in vivo models.21
Other approaches have also been used to develop a con-
venient assay for AMACR activity. The use of acyl-CoA oxidase
as a coupling enzyme enables a colorimetric assay to be per-
formed.22 This enzyme is not commercially available and
†Electronic supplementary information (ESI) available: 1H NMR spectra of syn-
thesised compounds; details of X-ray crystal structure determination of com-
pound 35; original data for Table 1; plots of fluorescence resulting from reaction
of sensors 33 and 34 with fluoride solutions. CCDC 1408401. For ESI and crystal-
lographic data in CIF or other electronic format see DOI: 10.1039/c5ob01541c
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rationally designed acyl-CoA inhibitors of AMACR are also
likely to inhibit the coupling enzyme, complicating the ana-
lysis. Coupled enzyme assays for other racemases/epimerases
have also been reported,23–27 but these are not readily adapt-
able to measuring AMACR activity.
Direct measurement of racemisation by MCR (the bacterial
homologue of AMACR from M. tuberculosis) using circular
dichroism has been reported,28 but this was not used for
inhibitor testing. Assays for several other racemases/
epimerases using circular dichroism27,29–31 or polarimetry32–34
have been developed, but these are generally low-throughput.
Moreover, acyl-CoA inhibitors with aromatic side-chains are
likely to undergo racemisation and this will complicate the
determination of inhibitor properties. Therefore, these assays
have serious limitations when determining inhibitor potency.
It has recently been reported that AMACR performs an
elimination reaction in which HF is eliminated from 3-fluoro-
2-methylacyl-CoAs (such as 1) to give unsaturated acyl-CoAs
(such as 2) (Scheme 1).35 This reaction is irreversible which
is an advantage compared to assays using isotopic
labels1,2,4,5,10,19 or ‘racemisation’17,18 as their reversibility
makes them more diﬃcult to interpret. In addition, the
2-methyl peaks of 1 and 2 are non-overlapping in the 1H NMR
spectrum, simplifying the measurement of substrate
conversion.
The elimination reaction also oﬀers the possibility of trans-
lation into a convenient, colorimetric or fluorometric assay by
manipulation of the substrate side-chain or by the use of
fluoride sensors. Assays using fluoride-specific electrodes to
measure enzyme activity have also been reported,36–38 but
these are generally low-throughput, require relatively large
volumes and are not easy to adapt to a microtitre plate
format.39 A number of highly sensitive molecular fluoride
sensors have been reported in the literature, which give an
increase in absorbance or fluorescence upon reaction with
fluoride. However, there are relatively few that can be used in
aqueous buﬀers.40–43 The development of a convenient high-
throughput assay is essential for the development of AMACR
as a drug target.
In this paper, the use of the AMACR-catalysed fluoride
elimination reaction for the characterisation of inhibitors is
investigated. Reduction in enzyme activity in the presence of
other known AMACR substrates and inhibitors was observed
by 1H NMR. The use of 3-fluoro-2-methylacyl-CoA substrates
with aromatic side-chains and fluoride sensors in order to
translate this reaction into a colorimetric or fluorescent assay
format is also investigated.
Results and discussion
Use of the elimination assay for inhibitor characterisation was
initially performed by incubation of recombinant human
AMACR 1A4 with a series of known ‘inhibitors’ (Table 1) and
substrate 1. The chosen ‘inhibitors’ included the known
AMACR substrates5 Fenoprofenoyl-CoA 3, Flurbiprofenoyl-CoA
4, Ibuprofenoyl-CoA 5, Ketoprofenoyl-CoA 6, and Naproxenoyl-
CoA 7. These are expected to behave as competitive inhibitors.
Also chosen was N-dodecyl-N-methyl-carbamoyl-CoA 8, a tran-
sition state analogue and the most potent AMACR inhibitor
described to date.18 Ebselen 9, Ebselen oxide 10 and Rose
Bengal 11 were also chosen for study as these are reported to
be good inhibitors of human AMACR 1A.19 Enzyme was
Scheme 1 The elimination reaction catalysed by AMACR.
Table 1 Inhibition of (2R,3R)-3-ﬂuoro-2-methyldecanoyl-CoA 1 con-
version by AMACR in the presence of known substrates and inhibitors.
Compound numbers for inhibitors refer to structures shown below.
Conversions are means of two replicate readings ± standard deviations
of the sample and are normalised to positive controls [(substrate 1 con-
version in presence of inhibitor/substrate 1 conversion in absence of
inhibitor) × 100]. Positive controls lacking inhibitor converted ca. 50% of
substrate 1 after 1 h incubation. See ESI Table 1 for absolute substrate
conversion levels in the presence of inhibitors and positive controls
Inhibitory
compound
Relative conversion
in presence
of inhibitor
Relative reduction
compared to
no inhibitor
None 100% 0%
3 74.9 ± 0.4% 25.1%
4 91.6 ± 2.0% 8.4%
5 74.1 ± 7.2% 25.9%
6 92.0 ± 8.6% 8.0%
7 88.8 ± 4.0% 11.2%
8 16.8 ± 1.8% 83.2%
9 <5% >95%
10 88.2 ± 5.4% 11.8%
11 <5% >95%
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pre-incubated with inhibitor for 10 min. to allow binding
before addition of substrate at 100 µM final concentration.
After 1 h the assay was terminated and the level of substrate
conversion was determined by 1H NMR. Control experiments
showed that the enzyme was fully active35 in the presence of
1 mM fluoride solution, indicating that any reduction in
activity was due to the presence of the ‘inhibitor’.
In the absence of inhibitor, ca. 50% of substrate 1 was con-
verted into unsaturated product 2 by active AMACR. Negative
controls containing heat-inactivated enzyme showed <5% con-
version of 1 to 2, levels of which did not change over the incu-
bation period. The presence of each ‘inhibitor’ (at 100 µM final
concentration) resulted in a reduction in the level of conversion
of 1 (Table 1). Compounds 3–7 showed moderate levels of inhi-
bition in most cases, with the most significant reduction in
activity occurring with Fenoprofenoyl-CoA 3 and Ibuprofenoyl-
CoA 5. Modest levels of inhibition are expected with com-
pounds 3–7, as the concentration of substrate 1 (100 µM) is sig-
nificantly above its reported Km value (21 µM).
35 These high
substrate concentrations will reduce the apparent eﬀect of com-
petitive inhibitors, but relative high concentrations of 1 are
required to perform the 1H NMR analyses. Incubation of the
known highly potent AMACR inhibitor 818 resulted in a very sig-
nificant reduction in activity (Fig. 1), consistent with it being a
good inhibitor (reported IC50 value of 98 nM
18). Ebselen 9 and
Rose Bengal 11 were also highly potent under the assay con-
ditions, with no detectable conversion of 1. In contrast,
Ebselen oxide 10 was a modest inhibitor, having a similar
potency to the alternative substrates 3–7. This result was sur-
prising as Wilson et al.19 report that 10 was their most potent
inhibitor (IC50 value of 790 nM), compared to 9 (IC50 value of
10 µM) and 11 (IC50 value of 2.8 µM). Ebselen 9 is reported to
be an irreversible inhibitor of AMACR,19 and IC50 values are an
inappropriate measure of potency as inhibition levels are
dependent on the rate of inactivation. Rose Bengal 11 is a non-
specific inhibitor of a number of enzymes, and inhibition
appears to be related to generation of reactive oxygen species
upon irradiation with UV light.44–46 The diﬀerences in observed
behaviour between the two studies probably results from the
diﬀerent modes of action for 9, 10 and 11, meaning that the
results of the two studies are not directly comparable.
Although AMACR inhibitor testing using this method oﬀers
a number of advantages, including irreversible formation of
the product and non-overlapping signals for substrate 1 and
product 2, the method is still low-throughput as 1H NMR is
used to quantify conversion levels. Translation of this method
to a colorimetric or fluorescent assay is therefore desirable.
In order to do this, synthesis of acyl-CoA substrates with
aromatic side-chains was investigated as it was anticipated
that the unsaturated product would absorb in the visible spec-
trum. Synthesis of the anti-substrates was desired, as syn-
substrates are prone to undergo non-enzymatic elimination.35
In the first synthesis, benzaldehyde 12 and the R-Evan’s auxi-
liary protected propanoic acid 13 were condensed to give
alcohol 14 (Scheme 2). However, treatment of 14 with DAST
resulted in loss of stereochemistry upon introduction of the
fluoride to give a mixture of diastereomers of 15. For aliphatic
side-chains, the replacement of the 3-hydroxy group with fluor-
ide proceeds via an SN2 mechanism with inversion of stereo-
chemistry. This loss of stereochemistry is probably due to an
SN1 reaction occurring, with consequent addition of fluoride
to both faces of the stabilised benzylic carbocation. Conversion
of 14 to the methyl ester 16 followed by treatment with DAST
also resulted in significant loss of stereochemistry on conver-
sion to 17, suggesting that steric hindrance by the chiral auxili-
ary was not the deciding factor.
Synthesis of the 4-nitrophenyl- derivative was investigated
(Scheme 3) in order to destabilise the carbocation intermedi-
ate and hence improve diastereoselectivity. Condensation of
4-nitrobenzaldehyde 18 with S-Evan’s auxiliary protected pro-
panoic acid 19 gave 20, which was converted to methyl ester
21. However, treatment with DAST still resulted in a mixture of
syn- and anti-22 (68% de). The diastereomeric selectivity was
somewhat improved compared to conversion of 16 to 17,
suggesting that a carbocation intermediate had been destabi-
lised and the SN2 reaction was now more favoured.
Fig. 1 Reduction of conversion of 1 to 2 in the presence of inhibitor 8.
Above, 1H NMR spectrum following incubation with active AMACR in the
presence of 8; below, 1H NMR spectrum of positive control containing
active AMACR in the absence of inhibitor. Red and green circles show
methyl group signals for substrate 1 and unsaturated product 2,
respectively.
Scheme 2 Synthesis of 15 and 17. Reagents and conditions: i: Bu2BOTf,
i-Pr2EtN, DCM, −78 °C, 99%; ii: NaOMe, MeOH, 0 °C, 36%; iii. DAST,
DCM, −78 °C. Stereochemical course of reaction iii: 14 to 15, 74%, 53%
de; 16 to 17, 53%, 50% de.
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In contrast, condensation of tert-butyl-protected propanoic
acid 23 with 4-nitrobenzaldehyde 18 gave 24 as a pair of
enantiomers. Treatment with DAST gave the desired ester 25
(Scheme 4).
Similarly, reaction of benzyl-protected propanoic acid 26
with 4-nitrobenzaldehyde 18 gave 27. Treatment with DAST
gave the desired anti-product 28 (Scheme 5). Removal of the
benzyl protecting group with TMSI gave acid 29. However, con-
version of the acid to the acyl-CoA ester 30 using CDI resulted
in formation of a significant amount of the eliminated acyl-
CoA ester 31, the expected enzymatic product. This substrate
and product mixture could not be easily separated. The elimi-
nation of 30 to give 31 is probably driven by the thermodynamic
stability of the conjugated product.
Incubation of a mixture of 30/31 with active AMACR con-
firmed that 30 was converted to 31, as judged by reduction of
the doublet at 0.96 ppm and appearance of the Me-group
singlet at 1.97 ppm (Fig. 2). A change in the ratio of the triplets
at 2.32 and 2.37 ppm (CH2 groups in the CoA side-chain) was
also observed. These changes were not observed when using
heat-inactivated enzyme, showing that the elimination was
enzyme-catalysed. Product 31 absorbs at a maximum wave-
length of <340 nm and this is not ideally suited for use in a
microtitre plate assay. It was anticipated that addition of
further electron-withdrawing groups or extension of the aro-
matic system would increase the wavelength of the product
chromophore to >340 nm, but this would result in higher
levels of HF elimination from the acid when conversion of the
acyl-CoA ester was attempted. Therefore, further development
of this approach was not undertaken.
A second approach to developing a colorimetric or fluore-
scent assay for AMACR is to utilise a molecular fluoride sensor
in order to measure the fluoride released during the enzymatic
reaction. An advantage of this approach is that it allows assay-
ing of a wide variety of potential AMACR substrates, including
those with alkyl side-chains.35 Although there are many fluor-
ide sensors reported, few of them can be used in aqueous
systems. Fluorescent sensors 32,42 33,40 34,47 and 3543 and the
colorimetric sensor 3641 (Fig. 3) were selected for investigation
Scheme 3 Synthesis of 22. Reagents and conditions: MgCl2, TMSCl,
i-Pr2EtN, EtOAc, rt, then TFA : MeOH 1 : 9, rt, 71%; ii: NaOMe, MeOH,
0 °C, 53%; iii: DAST, DCM, −78 °C. 69% (68% de).
Scheme 4 Synthesis of tert-butyl 3-ﬂuoro-2-methyl-3-(4-nitrophenyl)
propanoate 25 Reagents and conditions: i. LDA, THF, −78 °C, 52%;
ii. DAST, DCM, −78 °C, 51%.
Scheme 5 Synthesis of anti-3-ﬂuoro-2-methyl-3-(4-nitrophenyl)pro-
panoyl-CoA 30. Reagents and conditions: i: LDA, THF, −78 °C, separ-
ation of syn- and anti-isomers; 17% yield for syn-isomer; ii: DAST, DCM,
−78 °C, 42%; iii: TMSI, CHCl3, 40 °C, 90%; iv: CDI, DCM, rt, then CoA-Li3,
0.1 M NaHCO3 aq., THF, rt.
Fig. 2 Conversion of 3-ﬂuoro-2-methyl-3-(4-nitrophenyl)propanoyl-
CoA 30 by human AMACR 1A. Above, 1H NMR spectrum following incu-
bation with active AMACR; below, 1H NMR spectrum following incu-
bation with heat-inactivated AMACR. Red and green circles show methyl
group signals for substrate 30 and unsaturated product 31, respectively.
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due to their apparent sensitivity and compatibility with
aqueous systems.
Synthesis of these selected sensors and incubation with
fluoride in buﬀered aqueous solution was undertaken to vali-
date the method. Sensor 32 initially gave a low fluorescent
signal which rapidly increased with time, regardless of
whether fluoride was present or not. This was also true with
solutions prepared using highly purified water. It was con-
cluded that spontaneous loss of the silyl-protecting group
occurred due to the formation of the highly stabilised aromatic
fluorescein. Sensor 33, which has previously been used to
assay γ-butyrobetaine hydroxylase activity,40 was therefore
investigated. This sensor was more stable, but large variations
in signal intensity at low aqueous fluoride concentrations were
observed, limiting its use in enzymatic assays (ESI, Fig. S25†).
Fluorescent detection of fluoride was also attempted using the
‘turn oﬀ’ sensor 34. Reaction of strong nucleophiles such as
fluoride35 results in fluorescent quenching of 34 due to a weak-
ening of the interaction between the nitrogen and boron.
However, incubation of 34 with standard fluoride solutions
resulted in highly variable readings in aqueous solutions even
in the presence of high organic solvent concentrations (ESI,
Fig. S26 and S27†).
Sensor 35 was also investigated, as it is reported to be
highly sensitive and to work by a mechanism that does
not involve silyl-protecting group removal.43 Synthesis was
accomplished by modification of the literature procedure
(Scheme 6).43 2-Hydroxybenzaldehyde was protected with MeI
to give 37 and 2-aminoacetophenone was protected with acetyl
chloride to give 38. Compounds 37 and 38 were condensed
together under alkali conditions to give 39. Hydrolysis of the
acetyl group from 39, followed by cyclisation gave 40. Removal
of the O-methyl group with NaSEt gave 35, whose structure was
confirmed by X-ray crystallography (see ESI† for details).
However, no fluorescence was observed for 35 in the presence
of fluoride. It was noted that the spectroscopic data for 35 did
not match that reported in the literature.43
Finally, a colorimetric method for determining fluoride
concentrations was investigated. The protected cyanine dye
system 36 reported by Zhu et al.,41 was chosen since this is
reported to be a highly sensitive system. The required dye was
synthesised by reaction of lepidine 41 with ethyl iodide fol-
lowed by coupling of the product 42 with 4-hydroxybenzalde-
hyde to give 43 (Scheme 7). However, protection of 43 with
TBDMSiCl to give 36 could not be achieved using a number of
diﬀerent conditions, including those originally reported.41
Conclusions
The results herein demonstrate that the elimination reaction
catalysed by AMACR can be used to evaluate the potency of
inhibitors. Conversion of substrate 1 to product 2 and HF was
reduced in the presence of known AMACR substrates (acting as
competitive inhibitors) and known inhibitors. N-Dodecyl-N-
methyl-carbamoyl-CoA 8 gave the largest reduction in the con-
version of 1 to 2 of all the acyl-CoA esters, consistent with pre-
vious reports18 that it is a potent inhibitor. Some of the
inhibitors reported by Wilson et al.19 also potently inhibited
the enzyme. The throughput of this assay is not suﬃcient for
high-throughput screening purposes, but it may allow prelimi-
Fig. 3 Fluoride sensors selected for study.
Scheme 6 Synthesis of sensor 35. Reagents and conditions: i. 5% (w/v)
NaOH aq., MeOH, rt, 72%; ii. 5% (v/v) HCl aq., reﬂux, 62%; iii. NaSEt,
DMF, 140 °C, 80%.
Scheme 7 Attempted synthesis of ﬂuoride sensor 36. Reagents and
conditions: i: ethyl iodide, toluene, reﬂux, 89%; ii: 4-hydroxybenzalde-
hyde, piperidine, MeOH, reﬂux, 60%; iii: TBDMSiCl, pyridine, reﬂux, 0%;
iv: TBDMSiCl, NEt3, DCM, rt, 0%; v: TBDMSiCl, NEt3, CHCl3, reﬂux, 0%.
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nary characterisation of inhibitors identified through other
approaches and would be a useful secondary screen for inhibi-
tors identified using other methods.
Attempts to adapt the elimination assay to produce a colori-
metric or fluorescent read-out were not very successful. Acyl-
CoA substrates with aromatic side-chains were synthesised,
but the presence of the aromatic side-chain resulted in loss of
stereochemistry upon introduction of the fluoride leaving
group. Loss of stereochemical integrity limits the application
of these substrates as non-enzymatic elimination occurs in
substrates in which the methyl group and fluorine atom are in
a syn-arrangement. This approach is also limited by fluoride
elimination upon conversion of the acid to the acyl-CoA. The
results show that AMACR catalyses the elimination of fluoride
from acyl-CoAs with aromatic side-chains and hence extends
the range of known substrates.
The alternative approach of assaying AMACR activity by
quantifying fluoride using sensors was also not very success-
ful. Although there are several fluoride sensors reported for
use in aqueous solutions, the high levels of hydration of the
fluoride anion35 makes such methods slow and it can be
diﬃcult to achieve suﬃcient reproducibility.
Experimental
Sources of materials
All chemicals were obtained from the Sigma-Aldrich Chemical
Co. or Fisher Scientific Ltd and were used without further puri-
fication, unless otherwise noted. Reagents were of analytical
grade or equivalent (synthesis) or biochemical grade. Oasis
HLB cartridges were obtained from Waters Corporation. Con-
struction of the expression plasmid for human AMACR 1A has
been previously described.4 The Rosetta2 (DE3) expression
strain and auto-induction media system 1 were obtained from
Novagen. (2R,3R)-3-Fluoro-2-methyldecanoyl-CoA 1 was syn-
thesised as previously described.35 Fenoprofenoyl-CoA 3, Flur-
biprofenoyl-CoA 4, Ibuprofenoyl-CoA 5, Ketoprofenoyl-CoA 6
and Naproxenoyl-CoA 7 were synthesised as previously
described.5 Ebselen 9 and Ebselen oxide 10 were obtained
from Cayman Chemical. Compounds 1448 and 1649 were syn-
thesised by their reported methods. The PEGylated fluorescein
derivative 32 was synthesised by the method of Zheng et al.42
tert-Butyldimethylsilyl-protected fluorescein 33 was syn-
thesised by the method of Rydzik et al.40 The boronic acid
sensor 34 was synthesised by the method described by Sun
et al.47 Intermediates 37,50 38,51 39,52 and 4052 for the syn-
thesis of sensor 35 were produced by known methods. Inter-
mediates 4253 and 4353 required for the synthesis of 36 were
produced by known methods.
General experimental procedures
Solvents were removed using Büchi rotary evaporators. Thin
layer chromatography was performed on Merck silica alu-
minium plates 60 (F254) and UV light, potassium permanga-
nate or phosphomolibdic acid were used for visualisation.
Column chromatography was performed using Fisher silica gel
(particle size 35–70 micron). Purifications of acyl-CoA esters
were performed by solid phase extraction using Oasis HLB 6cc
(200 mg) extraction cartridges. Phosphate buﬀer was prepared
from monobasic and dibasic potassium phosphates at the
required proportion for 0.1 M pH 7.0 buﬀer. Optical rotations
were recorded on an Optical Activity AA-10 Automatic polari-
meter instrument and are reported in 10−1 deg cm2 g−1.
IR spectra were recorded on Perkin-Elmer RXI FTIR spectro-
meter instrument. NMR spectra were recorded on Bruker
Avance III 400.04 MHz or 500.13 MHz spectrometers in D2O or
CDCl3 and solvent was used as an internal standard. Shifts are
given in ppm and J values reported to 0.1 Hz. Multiplicities are
described as follows: s, singlet; d, doublet; t, triplet; q, quartet;
m, multiplet. Stock concentrations of acyl-CoA esters for assays
were determined using 1H NMR.35 Mass spectra were recorded
by ESI TOF at the University of Bath Mass Spectrometry
Service. High resolution mass spectra were recorded in ES
mode. Aqueous solutions for biological experiments were pre-
pared in 18.2 MΩ cm−1 Nanopure water and pH-adjusted with
aq. HCl or NaOH. Syntheses were carried out at ambient temp-
erature, unless otherwise specified. Solutions in organic sol-
vents were dried over anhydrous magnesium sulfate and
evaporated under reduced pressure.
Synthesis of N-dodecyl-N-methyl-carbamoyl-CoA (8)18
Compound 8 was synthesised by the method of Carnell et al.18
using 1-[dodecyl(methyl)carbamoyl]-3-methyl-1H-imidazol-3-
ium iodide (40.0 mg, 0.092 mmol) and CoA-Li3 (17.0 mg,
0.020 mmol) in a mixture of dilute aqueous sodium hydrogen
carbonate and THF. The crude aqueous product was freeze-
dried and purified with solid phase extraction to obtain a
white solid (7.1 mg). 1H NMR (500.13 MHz, CDCl3): δ 8.62 (1H,
s), 8.35 (1H, s), 6.15 (1H, d, J = 6.0 Hz), 4.57–4.48 (1H, m),
4.23–4.13 (2H, m), 3.97 (1H, s), 3.84 (3H, s), 3.81–3.76 (1H, m),
3.53–3.47 (1H, m), 3.39 (2H, t, J = 6.5 Hz), 3.35–3.22 (3H, m),
2.95–2.82 (4H, m), 2.38 (2H, t, J = 6.5 Hz), 1.55–1.35 (2H, m),
1.25–1.05 (18H, m), 0.87 (3H, s), 0.76 (3H, t, J = 7.0 Hz), 0.72
(3H, s); HRMS (ES) [M + 2Na − 3H]− Calcd. For
C35H60N8Na2O17P3S: 1035.2805, found 1035.3050.
Attempted synthesis of (R)-4-benzyl-3-[(2S,3S)-3-fluoro-2-
methyl-3-phenylpropanoyl]oxazolidin-2-one (15)
A solution of DAST (0.09 mL, 0.68 mmol) in anhydrous DCM
(1 mL) was added dropwise to a solution of 14 (230 mg,
0.68 mmol) in anhydrous DCM (3 mL) at −78 °C. The reaction
mixture was stirred at −78 °C for 2 h, then allowed to reach
ambient temperature. The reaction mixture was quenched by
the slow addition of water (5 mL). The organic layer was
washed with saturated NaHCO3 aq. and brine. The solution
was dried over MgSO4, filtered and then the solvent was
removed under reduced pressure. The product was purified by
column chromatography (Pe : EtOAc 5 : 1) to give 15 as a
mixture of diastereoisomers (200 mg, 87%, 50% de) as a
colourless oil. 1H NMR (400.04 MHz, CDCl3): δ Major dia-
stereomer (selected isolated peaks) 7.43–7.16 (10H, m), 5.63
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(1H, dd, J = 46.4, 9.8 Hz), 4.80–4.72 (1H, m), 3.30 (1H, dd, J =
13.4, 3.4 Hz), 2.83 (1H, dd, J = 13.4, 9.5 Hz), 1.02 (3H, d, J =
7.0 Hz); minor diastereomer (selected isolated peaks)
7.43–7.16 (10H, m), 5.69 (1H, dd, J = 47.5, 6.6 Hz), 3.24 (1H,
dd, J = 13.4, 3.3 Hz), 2.74 (1H, dd, J = 13.4, 9.7 Hz), 1.38 (3H,
dd, J = 6.8, 0.8 Hz).
Attempted synthesis of (2S,3S)-methyl-3-fluoro-2-methyl-3-
phenylpropanoate (17)
A solution of DAST (92 μL, 0.70 mmol) in anhydrous DCM
(1 mL) was added dropwise to a solution of 16 (135 mg,
0.70 mmol) in anhydrous DCM (4 mL) at −78 °C. The reaction
mixture was stirred at −78 °C for 1 h, then allowed to reach
ambient temperature. The reaction mixture was quenched by
the slow addition of water (5 mL). The organic layer was
washed with saturated NaHCO3 aq. and brine. The solution
was dried over MgSO4, filtered and then the solvent was
removed under reduced pressure. The product was purified by
column chromatography (Pe : EtOAc 20 : 1) to give 17 (100 mg,
72%, 50% de) as a colourless oil. 1H NMR54 (400.04 MHz,
CDCl3): δ Major diastereomer: 7.42–7.29 (5H, m), 5.54 (1H, dd,
J = 46.1, 9.5 Hz), 3.77 (3H, s), 3.07–2.97 (1H, m), 0.96 (3H, d,
J = 7.2 Hz); minor diastereomer: 7.42–7.29 (5H, m), 5.76 (1H,
dd, J = 46.7, 6.1 Hz), 3.63 (3H, s), 2.97–2.87 (1H, m), 1.26 (3H,
dd, J = 7.0, 0.8 Hz).
Synthesis of (S)-4-benzyl-3-[(2S,3S)-3-hydroxy-2-methyl-3-(4-
nitrophenyl)propanoyl]-oxazolidin-2-one (20)
A solution of dibutylboron triflate in DCM (1.0 M, 4.72 mL,
4.72 mmol) and diisopropylethylamine (0.90 mL, 5.14 mmol)
were added to a stirred solution of oxazolidinone 19 (1.000 g,
4.29 mmol) in 10 mL of DCM at −78 °C and the resulting solu-
tion was stirred for 30 min at this temperature. p-Nitrobenzal-
dehyde 18 (0.907 g, 6.00 mmol) in 3 mL of DCM was added
dropwise and the reaction mixture was stirred at −78 °C for
30 min and then allowed to reach ambient temperature. The
reaction was quenched by slow addition of phosphate buﬀer
(0.1 M, pH = 7.0, 10 mL), the organic layer was then washed
with 1 M HCl aq., then saturated NaHCO3 aq. and brine. The
solution was dried over MgSO4, filtered and then the solvent
was removed under reduced pressure. The product was puri-
fied by column chromatography (Pe : EtOAc 2 : 1) to give 20
(1.460 g, 89%) as a yellow solid. m.p. 136–138 °C; [α]21D = +59.0
(CHCl3, c = 0.43); IR (KBr disc, cm
−1): 3525.3, 1775.2, 1683.4
1H NMR (400.04 MHz, CDCl3): δ 8.22 (2H, d, J = 8.7 Hz), 7.59
(2H, d, J = 8.7 Hz), 7.38–7.27 (3H, m), 7.23–7.17 (2H, m),
5.28–5.24 (1H, m), 4.78–4.70 (1H, m), 4.30–4.20 (2H, m), 4.05
(1H, dq, J = 7.0, 2.8 Hz), 3.54–3.48 (1H, m), 3.26 (1H, dd, J =
13.4, 3.4 Hz), 2.82 (1H, dd, J = 13.4, 9.4 Hz), 1.13 (3H, d, J =
7.0 Hz). 13C NMR (100.60 MHz, CDCl3) δ 176.67, 152.86,
148.34, 147.27, 134.66, 129.35, 129.01, 127.54, 126.93, 123.45,
72.19, 66.34, 55.01, 43.95, 37.71, 9.99. HRMS (ES) [M + H]+
Calcd. for C20H21N2O6: 385.1400, Found: 385.1421; [M + Na]
+
Calcd. for C20H20N2NaO6: 407.1219, Found: 407.1216.
Synthesis of (2S,3S)-methyl 3-hydroxy-2-methyl-3-(4-
nitrophenyl)propanoate (21)
Compound 21 was synthesised by a new procedure: sodium
metal (49 mg, 2.13 mmol) was reacted with anhydrous MeOH
(20 mL), cooled to 0 °C, then treated with a solution of com-
pound 20 (511 mg, 1.33 mmol) in anhydrous MeOH (5 mL).
The resulting reaction mixture was stirred at 0 °C for 15 min.
The reaction was quenched by the slow addition of phosphate
buﬀer (0.1 M, pH = 7.0, 20 mL). The reaction mixture was
extracted with DCM (4 × 20 mL) and the combined organic
extracts were washed with brine, dried over MgSO4, filtered
and the solvents were removed under reduced pressure. The
product was purified by column chromatography (Pe : EtOAc
3 : 1) to give 21 (170 mg, 53%) as a yellow oil. 1H NMR55
(400.04 MHz, CDCl3): δ 8.23–8.17 (2H, m), 7.55–7.50 (2H, m),
5.24 (1H, m), 3.72 (3H, s), 3.32 (1H, d, J = 3.0 Hz), 2.79 (1H, dq,
J = 7.3, 3.4 Hz), 1.07 (3H, d, J = 7.3 Hz).
Synthesis of (2R,3R,S)-methyl-3-fluoro-2-methyl-3-(4-
nitrophenyl)propanoate (22)
A solution of DAST (90 μL, 0.69 mmol) in anhydrous DCM
(1 mL) was added dropwise to a solution of compound 21
(165 mg, 0.69 mmol) in anhydrous DCM (4 mL) at −78 °C. The
reaction mixture was stirred at −78 °C for 1 h, then allowed to
reach ambient temperature. The reaction mixture was
quenched by the slow addition of water (5 mL). The organic
layer was washed with saturated NaHCO3 aq. and brine. The
solution was dried over MgSO4, filtered and then the solvent
was removed under reduced pressure. The product was puri-
fied by column chromatography (Pe : EtOAc 20 : 1) to give 22
(93 mg, 56%, 77% de) as a colourless oil. 1H NMR
(400.04 MHz, CDCl3): δ Major diastereomer: 8.27–8.19 (2H, m),
7.53–7.47 (2H, m), 5.71 (1H, dd, J = 45.8, 8.3 Hz), 3.75 (3H, s),
3.08–3.00 (1H, m), 1.02 (3H, d, J = 7.2 Hz); minor diastereomer:
8.27–8.19 (2H, m), 7.53–7.47 (2H, m), 5.87 (1H, dd, J = 46.5,
5.8 Hz), 3.66 (3H, s), 3.00–2.85 (1H, m), 1.25 (3H, dd, J = 7.1,
0.9 Hz).
Synthesis of syn–tert-butyl 3-hydroxy-2-methyl-3-(4-
nitrophenyl)propanoate (24)
tert-Butyl propionate 23 (1.00 mL, 865 mg, 6.64 mmol) was dis-
solved in anhydrous THF (20 mL), cooled to −78 °C, then
lithium diisopropylamide in THF (2.0 M, 3.2 mL, 6.64 mmol)
was added dropwise and the reaction mixture was stirred at
this temperature for 30 min. 4-Nitrobenzaldehyde 18
(1004 mg, 6.64 mmol) in anhydrous THF (7 mL) was added to
the reaction mixture, stirred for 2 h and then the reaction
mixture was allowed to reach ambient temperature. The reac-
tion mixture was quenched by slow addition of saturated
NH4Cl aq. (20 mL), extracted with DCM. The organic layer was
washed with water and brine, dried over MgSO4, filtered and
the solvents were removed under reduced pressure. The
residue was purified by column chromatography (Pe : EtOAc
10 : 1) to give compound 24 (970 mg, 52%) as a yellow oil. 1H
NMR (400.04 MHz, CDCl3): δ 8.22–8.17 (2H, m), 7.55–7.50 (2H,
Paper Organic & Biomolecular Chemistry
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m), 5.18 (1H, dd, J = 3.5, 2.8 Hz), 3.55 (1H, d, J = 2.8 Hz), 2.67
(1H, dq, J = 7.2, 3.5 Hz), 1.44 (9H, s), 1.03 (3H, d, J = 7.2 Hz).
13C NMR (100.59 MHz, CDCl3) δ 175.20, 148.80, 147.16,
126.87, 123.37, 81.81, 72.46, 46.27, 27.93, 10.33. HRMS (ES) [M
+ Na]+ Calcd. for C14H19NNaO5: 304.1161, Found: 304.1160.
Synthesis of anti–tert-butyl 3-fluoro-2-methyl-3-(4-
nitrophenyl)propanoate (25)
A solution of DAST (94 µL, 0.71 mmol) in anhydrous DCM
(1 mL) was added dropwise to a solution of compound 24
(200 mg, 0.71 mmol) in anhydrous DCM (5 mL) at −78 °C. The
reaction mixture was stirred at −78 °C for 2 h, then allowed to
reach ambient temperature. The reaction mixture was
quenched by the slow addition of water (10 mL). The organic
layer was washed with saturated NaHCO3 aq. and brine. The
solution was dried over MgSO4, filtered and then the solvent
was removed under reduced pressure. The product was puri-
fied by column chromatography (Pe : EtOAc 30 : 1) to give 25
(102 mg, 51%) as white solid. 1H NMR (400.04 MHz, CDCl3):
δ 8.26–8.21 (2H, m), 7.55–7.48 (2H, m), 5.78 (1H, dd, J = 46.8,
6.4 Hz), 2.89–2.74 (1H, m), 1.36 (9H, s), 1.23 (3H, dd, J = 7.1,
0.9 Hz). 13C NMR (125.76 MHz, CDCl3) δ 171.83 (d, J = 3.9 Hz),
148.15, 144.46 (d, J = 20.2 Hz), 127.35 (d, J = 7.0 Hz), 123.68,
94.25 (d, J = 176.6 Hz), 81.64, 46.99 (d, J = 24.6 Hz), 28.00,
12.92 (d, J = 6.7 Hz). 19F NMR (470.52 MHz, CDCl3) δ −175.39.
HRMS (ES) [M + Na]+ Calcd. for C14H18FNNaO4: 306.1118,
Found: 306.1106.
Synthesis of syn-benzyl 3-hydroxy-2-methyl-3-(4-nitrophenyl)-
propanoate (27)
Benzyl propionate 26 (1.00 mL, 1.04 g, 6.33 mmol) was dis-
solved in anhydrous THF (20 mL), cooled to −78 °C, then LDA
in THF (2.0 M, 3.2 mL, 6.33 mmol) was added dropwise and
the reaction mixture was stirred at this temperature for
30 min. 4-Nitrobenzaldehyde 18 (956 mg, 6.33 mmol) in an-
hydrous THF (7 mL) was added to the reaction mixture, stirred
for 2 h and then the reaction mixture was allowed to reach
ambient temperature. Reaction mixture was quenched by slow
addition of saturated NH4Cl aq. (20 mL) and extracted with
DCM. The organic layer was washed with water and brine,
dried over MgSO4, filtered and the solvents were removed
under reduced pressure. The residue was purified by column
chromatography (Pe : EtOAc 10 : 1) to give compound 27
(519 mg, 26%) as a yellow oil. 1H NMR56 (400.04 MHz, CDCl3):
δ 8.19–8.12 (2H, m), 7.52–7.45 (2H, m), 7.38–7.26 (5H, m), 5.21
(1H, dd, J = 3.9, 3.2 Hz), 5.18–5.09 (2H, m), 3.21 (1H, d, J =
3.2 Hz), 2.84 (1H, dq, J = 7.2, 3.9 Hz), 1.12 (3H, d, J = 7.2 Hz).
HRMS (ES) [M + Na]+ Calcd. for C17H17NNaO5: 338.1004,
Found: 338.1006.
Synthesis of anti-benzyl 3-fluoro-2-methyl-3-(4-nitrophenyl)-
propanoate (28)
A solution of DAST (0.46 mL, 3.45 mmol) in anhydrous DCM
(10 mL) was added dropwise to a solution of compound 27
(989 mg, 3.14 mmol) in anhydrous DCM (20 mL) at −78 °C.
The reaction mixture was stirred at −78 °C for 2 h, then
allowed to reach ambient temperature. The reaction mixture
was quenched by the slow addition of water (20 mL). The
organic layer was washed with saturated NaHCO3 aq. and
brine. The solution was dried over MgSO4, filtered and then
the solvent was removed under reduced pressure. The product
was purified by column chromatography (Pe : EtOAc 10 : 1) to
give 28 (410 mg, 42%) as a colourless oil. 1H NMR
(500.13 MHz, CDCl3): δ 8.23–8.16 (2H, m), 7.48–7.41 (2H, m),
7.40–7.31 (5H, m), 5.74 (1H, dd, J = 45.7, 7.9 Hz), 5.23–5.14
(2H, m), 3.14–3.03 (1H, m), 1.06 (3H, d, J = 7.2 Hz). 13C NMR
(125.76 MHz, CDCl3) δ 172.25 (d, J = 4.2 Hz), 148.09, 143.91 (d,
J = 20.4 Hz), 135.34, 128.58, 128.45, 128.31, 127.14 (d, J =
7.1 Hz), 123.65, 93.78 (d, J = 177.6 Hz), 66.88, 46.03 (d, J =
24.5 Hz), 12.66 (d, J = 6.3 Hz). 19F NMR (470.52 MHz, CDCl3)
δ −176.09. HRMS (ES) [M + Na]+ Calcd. for C17H16FNNaO4:
340.0961, Found: 340.0947.
Synthesis of anti-3-fluoro-2-methyl-3-(4-nitrophenyl)propanoic
acid (29)
Compound 28 (216 mg, 0.68 mmol) was dissolved in an-
hydrous CHCl3 (10 mL), then TMSI (0.31 mL, 2.18 mmol) was
added and the reaction mixture was stirred at 40 °C for 16 h.
The reaction was quenched by slow addition of water (10 mL).
The organic layer was washed with water and brine, dried over
MgSO4, filtered and the solvent was removed under reduced
pressure. The residue was purified by column chromatography
(DCM :MeOH 10 : 1) to give 29 (139 mg, 90%) as a colourless
oil. 1H NMR (500.13 MHz, CDCl3): δ 8.32–8.25 (2H, m),
7.58–7.51 (2H, m), 5.74 (1H, dd, J = 45.7, 8.6 Hz), 3.11–3.01
(1H, m), 1.08 (3H, d, J = 7.2 Hz). 13C NMR (125.76 MHz, CDCl3)
δ 178.28, 148.32, 143.55 (d, J = 20.4 Hz), 127.40 (d, J = 6.9 Hz),
123.84, 93.68 (d, J = 177.1 Hz), 45.89 (d, J = 24.8 Hz), 12.81 (d,
J = 6.5 Hz). 19F NMR (470.52 MHz, CDCl3) δ −173.92. HRMS
(ES) [M + Na]+ Calcd. for C10H10FNNaO4: 250.0492, Found:
250.0477.
Attempted synthesis of anti-3-fluoro-2-methyl-3-(4-
nitrophenyl)propanoyl-CoA (30)
Compound 30 was prepared from the acid 29 using CDI and
CoA-Li3 according to the usual procedure
5 and purified with
solid phase extraction to give a white powder. 1H NMR analysis
showed that the product was a mixture of 30 and the elimi-
nated acyl-CoA ester 31 in an approximate 4 : 1 ratio. Full
characterisation was not possible, however selected peaks from
the 1H spectrum of 30 can be reported. 1H NMR (500.13 MHz,
D2O): δ 8.60 (1H, m), 8.34 (1H, m), 8.17 (2H, m), 7.53 (2H, m),
6.13 (1H, dd, J = 6.0, 2.0 Hz), 5.77–5.65 (2H, two overlapping
dd, J = 45.5, 7.5 Hz),), 4.53 (1H, m), 4.20–4.14 (2H, m), 3.98
(1H, s), 3.82–3.75 (1H, m), 3.55–3.48 (1H, m), 3.42–3.22 (5H,
m), 2.97 (2H, t, J = 6.8 Hz), 2.37 (2H, t, J = 6.8 Hz), 1.01 (3H, d,
J = 7.2 Hz), 0.87 (3H, s), 0.74 (3H, s).
Synthesis of 2-(2-hydroxyphenyl)-2,3-dihydroquinolin-4(1H)-
one (35)57
NaSEt (2.602 g, 30.94 mmol) was added to a stirred solution of
compound 40 (1.306 g, 5.16 mmol) in anhydrous DMF (46 mL)
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and the reaction mixture was stirred at 140 °C for 17 h. DMF
was removed under reduced pressure, and the residue was dis-
solved in EtOAc, washed with saturated NH4Cl aq. and the
organic layer was washed with water and brine, dried over
MgSO4, filtered and the solvents were removed under reduced
pressure. The residue was purified by column chromatography
(Pe : EtOAc 5 : 1) to give compound 35 (990 mg, 80%) as a
yellow solid. m.p. 179–181 °C, lit.57 165–167 °C. IR (KBr disk,
cm−1): 3096.5, 1639.1, 1607.6. 1H NMR (400.04 MHz, CDCl3):
δ 7.94 (1H, dd, J = 7.9, 1.5 Hz), 7.66 (1H, s), 7.41 (1H, ddd, J =
8.2, 7.2, 1.6 Hz), 7.24 (1H, ddd, J = 8.2, 7.5, 1.7 Hz), 7.16 (1H,
dd, J = 7.5, 1.6 Hz), 6.98–6.87 (3H, m), 6.83 (1H, d, J = 8.2 Hz),
4.89 (1H, ddd, J = 14.1, 3.6, 0.8 Hz), 4.70 (1H, br s), 3.10 (1H,
dd, J = 16.8, 14.1 Hz), 2.83 (1H, ddd, J = 16.8, 3.6, 1.8 Hz). 13C
NMR (125.77 MHz, CDCl3) δ 193.70, 155.21, 150.67, 135.51,
129.84, 127.90, 127.80, 124.86, 120.6, 120.46, 117.34, 117.25,
57.42, 43.62. HRMS (ES) [M + H]+ Calcd. for C15H14NO2:
240.1025, Found: 240.1005; [M + Na]+ Calcd. for C15H13NNaO2:
262.0844, Found: 262.0828. Details of the crystal structure
determination and parameters are reported in the ESI.†
Expression and purification of AMACR 1A
The plasmid for wild-type AMACR 1A4 was transformed into
competent Rosetta2 (DE3) cells and plated onto Lennox LB
media supplemented with 1% (w/v) agar, 30 µg mL−1 kanamy-
cin sulfate and 32 µg mL−1 chloramphenicol. A single colony
was picked into 10 mL Lennox LB media supplemented with
30 µg mL−1 kanamycin sulfate and 32 µg mL−1 chlorampheni-
col and grown overnight at 28 °C and 220 rpm. Growth of
starter culture at 37 °C resulted in ‘leaky’ expression of wild-
type AMACR. Starter culture was used to inoculate 500 mL
of LB media supplemented with the same antibiotics and 1×
auto-induction media and grown under the same conditions
overnight. Cells were harvested (Beckman JA-10 rotor, 9000
rpm, 16 000g, 30 min) and stored at −80 °C.
Cells (∼2 g) were re-suspended in 30 mL start buﬀer and
AMACR was purified as previously described.35 Fractions con-
taining AMACR were identified by SDS-PAGE analyses using
10% gels, pooled and dialysed into 10 mM NaH2PO4–NaOH,
pH 7.4. Protein concentrations were determined by absorbance
at 280 nm, and extinction coeﬃcients and molecular weights
for the His-tag protein calculated using Protparam (http://web.
expasy.org/protparam/).
1H NMR assay of AMACR activity
Enzyme assays with inhibitor were performed using a similar
method to previously reported.35 Enzyme (0.12 mg mL−1;
2.54 µM) was incubated with inhibitor (200 µM) in the pres-
ence of NaH2PO4–NaOH, pH 7.4 and ca. 88% (v/v) D2O (275
µL) for 10 min. An equal volume of (2R,3R)-3-fluoro-2-methyl-
decanoyl-CoA substrate 1 (200 µM) in buﬀer and D2O (275 µL)
was added to the enzyme/inhibitor mixture, and the assay was
incubated at 30 °C for 60 min. Enzyme was inactivated by
heating at 60 °C for 10 min before 1H NMR analysis. Conver-
sion of substrates was quantified by conversion of the 2-Me
doublet at ca. 1.0 ppm into a singlet at ca. 1.75 ppm, and
levels were corrected for non-enzymatic conversion in heat-
inactivated negative controls (<5% conversion).4,5 Reported
conversions are relative to positive controls lacking an inhibi-
tor (100% activity). Approximately 50% of substrate 1 was con-
verted to 2 after 1 h. Substrate conversion levels in the
presence and absence of each inhibitor are given in the ESI
(Table S1†) Concentrations of acyl-CoA substrate and inhibitor
stock solutions were determined by 1H NMR.5
Fluorescent detection of fluoride
Sensor 33 in DMSO (256 µM, 80 µL) was incubated with NaF
(0–640 µM, 20 µL) in 50 mM Tris-HCl, pH 7.5 in a black micro-
titre plate at ambient temperature. After 1 h, 50 µL of 50 mM
HEPES–NaOH, pH 7.0 was added. Fluorescence was deter-
mined using a FLUOstar Omega plate reader (BMG Labtech)
with excitation wavelength 480 nm and emission wavelength
520 nm.40 The graph is shown in the ESI as Fig. S25.†
Sensor 34 (final concentration 2 µM) was incubated with
fluoride (final concentrations 0–300 µM) in a total volume of
200 µL for 3 min. Reactions were carried out in 100% aceto-
nitrile (using tetra-n-butylammonium fluoride) or in 50 mM
NaH2PO4–NaOH, pH 7.4 (using NaF) and acetonitrile [1 : 19
(v/v)]. Fluorescence was determined using a FLUOstar Omega
plate reader (BMG Labtech) with excitation wavelength 350 nm
and emission wavelength 520 nm.47 The graphs are shown in
the ESI as Fig. S26 and S27,† respectively.
Abbreviations
AMACR α-Methylacyl-CoA racemase (P504S)
CoA Coenzyme A
CDI Carbonyldiimidazole
DAST Diethylaminosulfur trifluoride
DCM Dichloromethane
de Diastereomeric excess
DMF Dimethylformamide
DMSO Dimethylsulfoxide
D2O Deuterium oxide
EtOAc Ethyl acetate
EtOH Ethanol
ESI TOF Electrospray ionisation time-of-flight
HEPES 4-(2-Hydroxyethyl)-1-piperazineethane sulfonic
acid
HPLC High performance liquid chromatography
HRMS High resolution mass spectrometry
IR Infra-red
LB Luria-Bertani
MeI Methyl iodide
MeOH Methanol
m.p. Melting point
NaSEt Sodium ethanethiolate
NMR Nuclear magnetic resonance
Pe Petroleum ether
rpm Revolutions per minute
ppm Parts per million
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SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel
electrophoresis
TBDPSi- tert-Butyldiphenylsilyl-
THF Tetrahydrofuran
TMSI Trimethylsilyl iodide
Tris Tris(hydroxymethyl)methylamine
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